Incyte INCY announced positive results from two late-stage studies evaluating the safety and efficacy of its twice-daily ...

Ruxolitinib cream 1.5% shows “breakthrough” results as a treatment for prurigo nodularis, according to a presenter at the ...

ORLANDO -- More than 40% of patients with longstanding prurigo nodularis (PN) had significant improvement within 3 months of ...

Twice-daily application of ruxolitinib cream demonstrated an ability to reduce itching and blistering in prurigo nodularis, a ...

The Medicines and Healthcare products Regulatory Agency (MHRA) has approved Galderma’s Nemluvio (nemolizumab) to treat both atopic dermatitis and prurigo nodularis.

As Incyte strives to push its topical JAK inhibitor Opzelura into additional dermatology indications, the company’s latest ...

Co-moderator Joel Gelfand, MD, of the University of Pennsylvania in Philadelphia, asked whether the medication is "getting where it needs to be" in patients with thick prurigo nodules. Would ...

Incyte declines as data from phase III studies on povorcitinib, for the treatment of hidradenitis suppurativa, fail to meet investor expectations.

Shawn Kwatra, MD, FAAD, physician scientist at the University of Maryland Medical System, presented data at the American Academy of Dermatology 2025 annual conference on the rapid efficacy of topical ...

Incyte's revenues continues to grow, with full-year 2024 revenues reaching $4.2 billion, driven by JAKAFI and OPZELURA. Click ...